← Back to headlines
Summit Therapeutics Announces FDA PDUFA Date for Ivonescimab
Summit Therapeutics has outlined November 14 as the FDA PDUFA date for its ivonescimab Biologics License Application (BLA) and plans for HARMONi-3 PFS in the second half of 2026.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
